|[March 10, 2014]
Research and Markets: Investigation Report on China's Pemetrexed Market, 2009-2018: A Multi-Targeted Antimetabolite Antitumor Drug
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/hkzxdl/investigation)
has announced the addition of the "Investigation
Report on China Pemetrexed Market, 2009-2018" report to their
Pemetrexed, originally developed by Eli Lilly and Company, is a
multi-targeted antimetabolite antitumor drug. This product is with huge
growth potential in the market.
Approved by FDA in February 2004, pemetrexed is to treat unresectable
malignant pleural mesothelioma with cisplatin. It is the first drug
approved by FDA to treat the disease. In August 2004 pemetrexed was
approved as a second-line drug for local or metastatic non-small cell
So far pemetrexed (brand name ""Alimta"") has been approved to more than
60 countries worldwide. The product has been a best seller of Eli Lilly
and Company since it was launched, and its sales value keeps increasing
year after year. The CAGR of sales value of pemetrexed was 50.6% from
2004 to 2011. The sales value was only USD 140 million in 2004 and
reached USD 460 million in 2005. In 2011, it grew rapidly to USD 2.46
In the field of antitumor drugs in China, antimetabolic drug is one of
the most common types among traditional anti-tumor chemotherapy drugs.
Market size of pemetrxed in China has increased rapidly in recent
years. The CAGR of its sales value exceeded 70% from 2006 to 2013.
Pemetrexed was approved to clinical use in China in 2004. It was
approved to China in 2005 to treat malignant pleural mesothelioma. As a
multi-targeted antimetabolite antitumor drug, pemetrexed can treat
non-small cell lung cancer, pancreatic cancer and breast cancer with
little side effect. Mechanism of pemetrexed is better than traditional
antifolate drugs with great competitiveness in the field.
Hansoh Pharmaceutical and Qilu Pharmaceutical were approved to produce
APIs and preparation of this drug respectively in 2005 and 2006. Seeing
the great future in the market, a large number of manufacturers start to
produce the drug. In 2005, many domestic manufacturers began to apply
for the production of raw materials and injections. The competition
becomes more intense every day.
From 2005 to 2010, Eli Lilly and Company occupied most of Chinese sample
hospital market. However, Qilu Pharmaceutical and Hansoh Pharmaceutical
has caught up with Eli Lilly and Company since 2011. The main reason is
that drugs made within the country seize more market share with
relatively low price. As a result, the market is mostly occupied by Qilu
Pharmaceutical, Hansoh Pharmaceutical and Eli Lilly and Company.
By the end of 2013, over 10 manufacturers in China have been approved to
produce pemetrexed in China by SFDA. It is estimated that the pemetrexed
market in China will become increasingly competitive in the future. As
environment pollution intensifies, population aging increases and
lifestyle changes, incidence of cancer in China keeps rising, leading to
rapid growth in antitumor drug market in China.
Key Topics Covered:
1 Relevant Concepts of Pemetrexed
2 Market Overview of Pemetrexed in China, 2009-2013
3 Investigation on Sales Value of Pemetrexed in China, 2009-2013
4 Investigation on Market Share of Major Pemetrexed Manufacturers in
5 Investigation on Market Size of Pemetrexed by Dosage Form in China,
6 Reference Price of Pemetrexed Produced by Different Enterprises in
China Hospital Market
7 Prospect of China Pemetrexed Market, 2014-2018
- Qilu Pharmaceutical Co., Ltd.
- Hansoh Pharmaceutical
- LILLY France
- Dezhou Pharmaceutical Co., Ltd.
- Nanjing Pharmaceutical Factory Co., Ltd.
- Eli Lilly and Company
- Nanjing Yadong Qitian Pharmaceutical Co., Ltd.
- Jiangsu Aosaikang Pharmaceutical Co., Ltd.
For more information visit http://www.researchandmarkets.com/research/hkzxdl/investigation
[ Back To Telecom Signaling's Homepage ]